Androgen deprivation of prostate cancer: Leading to a therapeutic dead end

Cancer Letters

Volumn 367, Issue 1, 2015, Pages 12-17

  Katzenwadel, Arndt ^a   Wolf, Philipp ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Androgen deprivation therapy; Castration resistance; Molecular alterations; Prostate cancer

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANDROSTANOLONE; BETA CATENIN; CD133 ANTIGEN; ENZALUTAMIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; KERATINOCYTE GROWTH FACTOR; LYMPHOID ENHANCER FACTOR 1; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL X; PROTEIN MCL 1; PROTEIN MYB; PROTEIN P27; RECEPTOR FOR ACTIVATED C KINASE 1; SOMATOMEDIN BINDING PROTEIN 1; STEM CELL ANTIGEN 1; TESTOSTERONE; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN; WNT PROTEIN; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANDROGEN DEPRIVATION THERAPY; ANEMIA; APOPTOSIS; CANCER GROWTH; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE ARREST; CELL CYCLE REGULATION; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; FATIGUE; GENE EXPRESSION; GYNECOMASTIA; HOT FLUSH; HUMAN; MUSCLE ATROPHY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR BINDING; SEXUAL DYSFUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; STEM CELL; TRANSCRIPTION INITIATION; TREATMENT OUTCOME; TUMOR CELL; UPREGULATION; ANIMAL; DISEASE COURSE; DRUG DESIGN; DRUG EFFECTS; DRUG RESISTANCE; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; MORTALITY; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; TUMOR RECURRENCE;

ANDROGEN ANTAGONISTS; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DISEASE PROGRESSION; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; MOLECULAR TARGETED THERAPY; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84939267751     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.06.021     Document Type: Review

References (97)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin 2014, 64(1):9-29.
2. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 2013, 49(6):1374-1403.
3. Huggins C., Hodges C.V. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941, 1:293-297.
4. Assikis V.J., Simons J.W. Novel therapeutic strategies for androgen-independent prostate cancer: an update. Semin. Oncol 2004, 31(2 Suppl. 4):26-32.
5. Sharifi N., Gulley J.L., Dahut W.L. Androgen deprivation therapy for prostate cancer. JAMA 2005, 294(2):238-244.
6. Harle L.K., Maggio M., Shahani S., Braga-Basaria M., Basaria S. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin. Adv. Hematol. Oncol 2006, 4(9):687-696.
7. Michaelson M.D., Cotter S.E., Gargollo P.C., Zietman A.L., Dahl D.M., Smith M.R. Management of complications of prostate cancer treatment. CA Cancer J. Clin 2008, 58(4):196-213.
8. Rhee H., Gunter J.H., Heathcote P., Ho K., Stricker P., Corcoran N.M., et al. Adverse effects of androgen deprivation therapy in prostate cancer and their management. BJU Int 2015, 115(Suppl. 5):3-13.
9. Crawford E.D., Moul J.W. ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury. Oncology (Williston Park) 2015, 29(1):55-58.
10. Carneiro A., Sasse A.D., Wagner A.A., Peixoto G., Kataguiri A., Neto A.S., et al. Cardiovascular events associated with androgen deprivation therapy in patients with prostate cancer: a systematic review and meta-analysis. World J. Urol 2014, 10.1007/s00345-014-1439-6.
11. Collier A., Ghosh S., McGlynn B., Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Am. J. Clin. Oncol 2012, 35(5):504-509.
12. Shahinian V.B., Kuo Y.F., Freeman J.L., Goodwin J.S. Risk of the "androgen deprivation syndrome" in men receiving androgen deprivation for prostate cancer. Arch. Intern. Med 2006, 166(4):465-471.
13. Harris W.P., Mostaghel E.A., Nelson P.S., Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Urol 2009, 6(2):76-85.
14. Pienta K.J., Bradley D. Mechanisms underlying the development of androgen-independent prostate cancer. Clin. Cancer Res 2006, 12(6):1665-1671.
15. Tangen C.M., Faulkner J.R., Crawford E.D., Thompson I.M., Hirano D., Eisenberger M., et al. Ten-year survival in patients with metastatic prostate cancer. Clin. Prostate Cancer 2003, 2(1):41-45.
16. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med 2004, 351(15):1513-1520.
17. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med 2004, 351(15):1502-1512.
18. Niraula S., Tannock I.F. Broadening horizons in medical management of prostate cancer. Acta Oncol 2011, 50(Suppl. 1):141-147.
19. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324(5928):787-790.
20. de Bono J.S., Logothetis C.J., Molina A., Fizazi K., North S., Chu L., et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med 2011, 364(21):1995-2005.
21. Dhingra R., Sharma T., Singh S., Sharma S., Tomar P., Malhotra M., et al. Enzalutamide: a novel anti-androgen with prolonged survival rate in CRPC patients. Mini Rev. Med. Chem 2013, 13(10):1475-1486.
22. Scher H.I., Fizazi K., Saad F., Taplin M.E., Sternberg C.N., Miller K., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med 2012, 367(13):1187-1197.
23. Ryan C.J., Smith M.R., de Bono J.S., Molina A., Logothetis C.J., de Souza P., et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med 2013, 368(2):138-148.
24. Green S.M., Mostaghel E.A., Nelson P.S. Androgen action and metabolism in prostate cancer. Mol. Cell. Endocrinol 2012, 360(1-2):3-13.
25. Koivisto P., Kononen J., Palmberg C., Tammela T., Hyytinen E., Isola J., et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997, 57(2):314-319.
26. Bubendorf L., Kononen J., Koivisto P., Schraml P., Moch H., Gasser T.C., et al. Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays. Cancer Res 1999, 59(4):803-806.
27. Culig Z., Hobisch A., Cronauer M.V., Cato A.C., Hittmair A., Radmayr C., et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol 1993, 7(12):1541-1550.
28. Taplin M.E., Rajeshkumar B., Halabi S., Werner C.P., Woda B.A., Picus J., et al. Androgen receptor mutations in androgen-independent prostate cancer: cancer and Leukemia Group B Study 9663. J. Clin. Oncol 2003, 21(14):2673-2678.
29. Zhao X.Y., Malloy P.J., Krishnan A.V., Swami S., Navone N.M., Peehl D.M., et al. Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor. Nat. Med 2000, 6(6):703-706.
30. Gregory C.W., He B., Johnson R.T., Ford O.H., Mohler J.L., French F.S., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 2001, 61(11):4315-4319.
31. Halkidou K., Gnanapragasam V.J., Mehta P.B., Logan I.R., Brady M.E., Cook S., et al. Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene 2003, 22(16):2466-2477.
32. Godoy A.S., Sotomayor P.C., Villagran M., Yacoub R., Montecinos V.P., McNerney E.M., et al. Altered corepressor SMRT expression and recruitment to target genes as a mechanism that change the response to androgens in prostate cancer progression. Biochem. Biophys. Res. Commun 2012, 423(3):564-570.
33. Zhang Y., Linn D., Liu Z., Melamed J., Tavora F., Young C.Y., et al. EBP1, an ErbB3-binding protein, is decreased in prostate cancer and implicated in hormone resistance. Mol. Cancer Ther 2008, 7(10):3176-3186.
34. Montgomery R.B., Mostaghel E.A., Vessella R., Hess D.L., Kalhorn T.F., Higano C.S., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008, 68(11):4447-4454.
35. Stanbrough M., Bubley G.J., Ross K., Golub T.R., Rubin M.A., Penning T.M., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006, 66(5):2815-2825.
36. Twiddy A.L., Leon C.G., Wasan K.M. Cholesterol as a potential target for castration-resistant prostate cancer. Pharm. Res 2011, 28(3):423-437.
37. Guo Z., Dai B., Jiang T., Xu K., Xie Y., Kim O., et al. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell 2006, 10(4):309-319.
38. Kraus S., Gioeli D., Vomastek T., Gordon V., Weber M.J. Receptor for activated C kinase 1 (RACK1) and Src regulate the tyrosine phosphorylation and function of the androgen receptor. Cancer Res 2006, 66(22):11047-11054.
39. Dai B., Chen H., Guo S., Yang X., Linn D.E., Sun F., et al. Compensatory upregulation of tyrosine kinase Etk/BMX in response to androgen deprivation promotes castration-resistant growth of prostate cancer cells. Cancer Res 2010, 70(13):5587-5596.
40. Malinowska K., Neuwirt H., Cavarretta I.T., Bektic J., Steiner H., Dietrich H., et al. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocr. Relat. Cancer 2009, 16(1):155-169.
41. Yuan X., Cai C., Chen S., Chen S., Yu Z., Balk S.P. Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 2014, 33(22):2815-2825.
42. Gan L., Chen S., Wang Y., Watahiki A., Bohrer L., Sun Z., et al. Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer. Cancer Res 2009, 69(21):8386-8394.
43. Seruga B., Ocana A., Tannock I.F. Drug resistance in metastatic castration-resistant prostate cancer. Nat. Rev. Clin. Oncol 2011, 8(1):12-23.
44. Neto A.S., Tobias-Machado M., Wroclawski M.L., Fonseca F.L., Pompeo A.C., Del Giglio A. Molecular oncogenesis of prostate adenocarcinoma: role of thehuman epidermal growth factor receptor 2 (HER-2/neu). Tumori 2010, 96(5):645-649.
45. Traish A.M., Morgentaler A. Epidermal growth factor receptor expression escapes androgen regulation in prostate cancer: a potential molecular switch for tumour growth. Br. J. Cancer 2009, 101(12):1949-1956.
46. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 1994, 54(20):5474-5478.
47. Kojima S., Inahara M., Suzuki H., Ichikawa T., Furuya Y. Implications of insulin-like growth factor-I for prostate cancer therapies. Int. J. Urol 2009, 16(2):161-167.
48. Culig Z., Hobisch A., Bartsch G., Klocker H. Androgen receptor - an update of mechanisms of action in prostate cancer. Urol. Res 2000, 28(4):211-219.
49. Weber M.J., Gioeli D. Ras signaling in prostate cancer progression. J. Cell. Biochem 2004, 91(1):13-25.
50. Peraldo-Neia C., Migliardi G., Mello-Grand M., Montemurro F., Segir R., Pignochino Y., et al. Epidermal growth factor receptor (EGFR) mutation analysis, gene expression profiling and EGFR protein expression in primary prostate cancer. BMC Cancer 2011, 11:31.
51. Di Lorenzo G., Tortora G., Armiento F.P.D., De Rosa G., Staibano S., Autorino R., et al. Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin. Cancer Res 2002, 8(11):3438-3444.
52. Craft N., Shostak Y., Carey M., Sawyers C.L. A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med 1999, 5(3):280-285.
53. Yeh S., Lin H.K., Kang H.Y., Thin T.H., Lin M.F., Chang C. From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. Proc. Natl. Acad. Sci. U.S.A. 1999, 96(10):5458-5463.
54. Wen Y., Hu M.C., Makino K., Spohn B., Bartholomeusz G., Yan D.H., et al. HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. Cancer Res 2000, 60(24):6841-6845.
55. Zhau H.Y., Zhou J., Symmans W.F., Chen B.Q., Chang S.M., Sikes R.A., et al. Transfected neu oncogene induces human prostate cancer metastasis. Prostate 1996, 28(2):73-83.
56. Chinni S.R., Yamamoto H., Dong Z., Sabbota A., Bonfil R.D., Cher M.L. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol. Cancer Res 2008, 6(3):446-457.
57. Carrion-Salip D., Panosa C., Menendez J.A., Puig T., Oliveras G., Pandiella A., et al. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands. Int. J. Oncol 2012, 41(3):1128-1138.
58. Gravis G., Bladou F., Salem N., Goncalves A., Esterni B., Walz J., et al. Results from a monocentric phase II trial of erlotinib in patients with metastatic prostate cancer. Ann. Oncol 2008, 19(9):1624-1628.
59. Pezaro C., Rosenthal M.A., Gurney H., Davis I.D., Underhill C., Boyer M.J., et al. An open-label, single-arm phase two trial of gefitinib in patients with advanced or metastatic castration-resistant prostate cancer. Am. J. Clin. Oncol 2009, 32(4):338-341.
60. Boccardo F., Rubagotti A., Conti G., Battaglia M., Cruciani G., Manganelli A., et al. Prednisone plus gefitinib versus prednisone plus placebo in the treatment of hormone-refractory prostate cancer: a randomized phase II trial. Oncology 2008, 74(3-4):223-228.
61. Ziada A., Barqawi A., Glode L.M., Varella-Garcia M., Crighton F., Majeski S., et al. The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 2004, 60(4):332-337.
62. Agus D.B., Sweeney C.J., Morris M.J., Mendelson D.S., McNeel D.G., Ahmann F.R., et al. Efficacy and safety of single-agent pertuzumab (rhuMAb 2C4), a human epidermal growth factor receptor dimerization inhibitor, in castration-resistant prostate cancer after progression from taxane-based therapy. J. Clin. Oncol 2007, 25(6):675-681.
63. Knudsen B.S., Edlund M. Prostate cancer and the met hepatocyte growth factor receptor. Adv. Cancer Res 2004, 91:31-67.
64. Verras M., Lee J., Xue H., Li T.H., Wang Y., Sun Z. The androgen receptor negatively regulates the expression of c-Met: implications for a novel mechanism of prostate cancer progression. Cancer Res 2007, 67(3):967-975.
65. Liu T., Mendes D.E., Berkman C.E. From AR to c-Met: androgen deprivation leads to a signaling pathway switch in prostate cancer cells. Int. J. Oncol 2013, 43(4):1125-1130.
66. Smith D.C., Smith M.R., Sweeney C., Elfiky A.A., Logothetis C., Corn P.G., et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J. Clin. Oncol 2013, 31(4):412-419.
67. Fay A.P., Albiges L., Bellmunt J. Current role of cabozantinib in metastatic castration-resistant prostate cancer. Expert Rev. Anticancer Ther 2015, 15(2):151-156.
68. Krajewska M., Krajewski S., Epstein J.I., Shabaik A., Sauvageot J., Song K., et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am. J. Pathol 1996, 148(5):1567-1576.
69. Anvari K., Seilanian Toussi M., Kalantari M., Naseri S., Karimi Shahri M., Ahmadnia H., et al. Expression of Bcl-2 and Bax in advanced or metastatic prostate carcinoma. Urol. J. 2012, 9(1):381-388.
70. Catz S.D., Johnson J.L. BCL-2 in prostate cancer: a minireview. Apoptosis 2003, 8(1):29-37.
71. Srivastava S.K., Bhardwaj A., Singh S., Arora S., McClellan S., Grizzle W.E., et al. Myb overexpression overrides androgen depletion-induced cell cycle arrest and apoptosis in prostate cancer cells, and confers aggressive malignant traits: potential role in castration resistance. Carcinogenesis 2012, 33(6):1149-1157.
72. Sternberg C.N., Dumez H., Van Poppel H., Skoneczna I., Sella A., Daugaard G., et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer. Ann. Oncol 2009, 20(7):1264-1269.
73. Majumder P.K., Sellers W.R. Akt-regulated pathways in prostate cancer. Oncogene 2005, 24(50):7465-7474.
74. Courtney K.D., Corcoran R.B., Engelman J.A. The PI3K pathway as drug target in human cancer. J. Clin. Oncol 2010, 28(6):1075-1083.
75. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275(5308):1943-1947.
76. Wang S., Gao J., Lei Q., Rozengurt N., Pritchard C., Jiao J., et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 2003, 4(3):209-221.
77. Makhov P.B., Golovine K., Kutikov A., Teper E., Canter D.J., Simhan J., et al. Modulation of Akt/mTOR signaling overcomes sunitinib resistance in renal and prostate cancer cells. Mol. Cancer Ther 2012, 11(7):1510-1517.
78. Michaelson M.D., Oudard S., Ou Y.C., Sengelov L., Saad F., Houede N., et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J. Clin. Oncol 2014, 32(2):76-82.
79. Yokoyama N.N., Shao S., Hoang B.H., Mercola D., Zi X. Wnt signaling in castration-resistant prostate cancer: implications for therapy. Am. J. Clin. Exp. Urol 2014, 2(1):27-44.
80. de la Taille A., Rubin M.A., Chen M.W., Vacherot F., de Medina S.G., Burchardt M., et al. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin. Cancer Res 2003, 9(5):1801-1807.
81. Kypta R.M., Waxman J. Wnt/beta-catenin signalling in prostate cancer. Nat. Rev. Urol 2012, 9(8):418-428.
82. Kelly W.K., Halabi S., Carducci M., George D., Mahoney J.F., Stadler W.M., et al. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J. Clin. Oncol 2012, 30(13):1534-1540.
83. Tang Y., Wang L., Goloubeva O., Khan M.A., Zhang B., Hussain A. Divergent effects of castration on prostate cancer in TRAMP mice: possible implications for therapy. Clin. Cancer Res 2008, 14(10):2936-2943.
84. Tang Y., Hamburger A.W., Wang L., Khan M.A., Hussain A. Androgen deprivation and stem cell markers in prostate cancers. Int. J. Clin. Exp. Pathol 2009, 3(2):128-138.
85. Lin T.H., Lee S.O., Niu Y., Xu D., Liang L., Li L., et al. Differential androgen deprivation therapies with anti-androgens casodex/bicalutamide or MDV3100/Enzalutamide versus anti-androgen receptor ASC-J9(R) Lead to promotion versus suppression of prostate cancer metastasis. J. Biol. Chem 2013, 288(27):19359-19369.
86. Gingrich J.R., Barrios R.J., Kattan M.W., Nahm H.S., Finegold M.J., Greenberg N.M. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res 1997, 57(21):4687-4691.
87. Ryan C.J., Shah S., Efstathiou E., Smith M.R., Taplin M.E., Bubley G.J., et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin. Cancer Res 2011, 17(14):4854-4861.
88. Jennbacken K., Tesan T., Wang W., Gustavsson H., Damber J.E., Welen K. N-cadherin increases after androgen deprivation and is associated with metastasis in prostate cancer. Endocr. Relat. Cancer 2010, 17(2):469-479.
89. Lee Y.C., Cheng C.J., Huang M., Bilen M.A., Ye X., Navone N.M., et al. Androgen depletion up-regulates cadherin-11 expression in prostate cancer. J. Pathol 2010, 221(1):68-76.
90. Kleeberger W., Bova G.S., Nielsen M.E., Herawi M., Chuang A.Y., Epstein J.I., et al. Roles for the stem cell associated intermediate filament Nestin in prostate cancer migration and metastasis. Cancer Res 2007, 67(19):9199-9206.
91. Fahrenholtz C.D., Beltran P.J., Burnstein K.L. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts. Mol. Cancer Ther 2013, 12(4):394-404.
92. Thomas C., Lamoureux F., Crafter C., Davies B.R., Beraldi E., Fazli L., et al. Synergistic targeting of PI3K/AKT pathway and androgen receptor axis significantly delays castration-resistant prostate cancer progression in vivo. Mol. Cancer Ther 2013, 12(11):2342-2355.
93. Voskoboynik M., Staffurth J., Malik Z., Sweeney C., Chowdhury S. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer. Expert Rev. Anticancer Ther 2014, 14(11):1253-1256.
94. Suzman D.L., Antonarakis E.S. Castration-resistant prostate cancer: latest evidence and therapeutic implications. Ther. Adv. Med. Oncol 2014, 6(4):167-179.
95. Sardana G., Diamandis E.P. Biomarkers for the diagnosis of new and recurrent prostate cancer. Biomark. Med 2012, 6(5):587-596.
96. Bhavsar T., McCue P., Birbe R. Molecular diagnosis of prostate cancer: are we up to age?. Semin. Oncol 2013, 40(3):259-275.
97. Sweeney C.J. Insights into E3805: the CHAARTED trial. Future Oncol 2015, 11(6):897-899.